EBOV GP Specific Neutra™ Antibody Products
Product listAre you struggling with the highly pathogenic Ebola virus, the complexities of studying its entry mechanisms, or the urgent need for reliable tools for therapeutic and vaccine development? Creative Biolabs' EBOV GP Specific Neutra™ Antibody Products empower your research with high-affinity, functionally validated neutralizing antibodies, engineered through advanced recombinant technology and rigorous pseudovirus-based neutralization assays to accelerate your antiviral discovery pipeline.
Introduction to Ebola Virus Envelope Glycoprotein (EBOV GP)
The Ebola virus envelope glycoprotein (EBOV GP) is the sole viral surface protein and the principal determinant of viral entry, pathogenesis, and host immune response. It is indispensable for receptor binding, cellular fusion, and virion infectivity, making it the primary target for neutralizing antibodies and vaccine design. EBOV GP is a trimeric type I transmembrane protein expressed on the virion surface. It is transcribed as a precursor polypeptide (GP0) that is cleaved by furin into two subunits: the receptor-binding subunit (GP1) and the membrane-fusion subunit (GP2).
- Structural Insights
The prefusion trimer adopts a chalice-like shape, with GP1 forming the outer cap and GP2 forming the stalk and transmembrane anchor. Key structural regions include the receptor-binding domain (RBD), the glycan cap, the mucin-like domain (highly glycosylated and immunodominant), and the internal fusion loop in GP2. High-resolution cryo-EM structures have revealed the conformational changes required for membrane fusion and defined precise epitopes for potent neutralizing antibodies.
Fig.1 Analysis of glycosylation in EBOV GP through sequence and structural examination.1
- Resistance and Signaling Pathways
EBOV GP mediates attachment to host cells via interactions with multiple receptors (e.g., NPC1, TAM kinases, integrins). Successful entry disrupts host endothelial cell integrity and triggers a dysregulated immune response, characterized by a "cytokine storm" and impaired interferon signaling, leading to severe hemorrhagic fever and multi-organ failure.
- Clinical Impact
Ebola Virus Disease (EVD) is a severe, often fatal illness with high epidemic potential. Outbreaks pose significant public health emergencies, underscoring the critical need for effective countermeasures.
-
Antibodies Against EBOV GP
Neutralizing antibodies targeting EBOV GP are the cornerstone of therapeutic and prophylactic strategies. They primarily work by:- Blocking receptor attachment via the GP1 RBD or glycan cap.
- Inhibiting membrane fusion by targeting the GP2 fusion loop or stalk region.
- Orchestrating Fc-mediated effector functions (e.g., ADCC) to clear infected cells.
Applications of Anti-EBOV GP Neutralizing Antibodies
Fig.2 Interactions with GP and viral neutralization by a panel of rabbit monoclonal antibodies.2
- Therapeutic Intervention for EVD
Monoclonal antibody cocktails targeting non-overlapping epitopes on EBOV GP have become the standard of care, significantly reducing mortality. These antibodies neutralize free virions, block cellular entry, and promote immune clearance. Their deployment in recent outbreaks has validated the critical role of GP-directed neutralization in treating acute infection and improving survival rates.
- Post-Exposure Prophylaxis and Outbreak Control
Anti-EBOV GP antibodies provide crucial passive immunity for high-risk individuals, such as healthcare workers or close contacts of confirmed cases. Administration following suspected exposure can prevent the onset of disease, effectively containing the spread of the outbreak. This application is vital for ring vaccination strategies and protecting frontline personnel in outbreak settings.
- Vaccine Development and Efficacy Evaluation
EBOV GP is the key antigen in all licensed Ebola vaccines. High-quality anti-GP neutralizing antibodies are essential tools for: Characterizing the immunogenicity of vaccine candidates; Measuring neutralizing antibody titers in vaccine sera to correlate with protection; Performing competitive ELISA assays to map immune responses to critical protective epitopes.
Our Anti-EBOV GP Neutralizing Antibodies
Creative Biolabs delivers a premier suite of reagents designed for the most demanding Ebola virus research:
- High Neutralization Potency: Validated using authentic EBOV or robust pseudovirus neutralization assays.
- Precise Epitope Coverage: Antibodies targeting major antigenic sites: GP1 RBD, glycan cap, fusion loop, and GP2 stalk.
- Exceptional Specificity & Affinity: Low cross-reactivity, ensuring accurate detection and measurement in complex biological samples.
- Rigorously Validated for Multiple Applications: Optimized and guaranteed performance in ELISA, Western Blot, Immunofluorescence, and Neutralization assays.
- Consistent & Reproducible: Manufactured under stringent quality controls to ensure batch-to-batch reliability for your critical projects.
Creative Biolabs is your trusted partner in combating high-threat pathogens. We combine deep scientific knowledge with cutting-edge platform technology to provide researchers with powerful, reliable tools that accelerate timelines from discovery to development. Our EBOV GP Specific Neutra™ Antibody Products embody this commitment. Contact us; we offer the quality and validation necessary to advance your therapeutic, vaccine, and diagnostic programs.
References
- Peng, Weiwei, et al. "Glycan shield of the ebolavirus envelope glycoprotein GP." Communications biology 5.1 (2022): 785. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.1038/s42003-022-03767-1
- Donnellan, Francesca R., et al. "A broadly-neutralizing antibody against Ebolavirus glycoprotein that potentiates the breadth and neutralization potency of other antibodies." bioRxiv (2024). Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.1101/2024.06.21.600001
